Thromb Haemost 1966; 25(01/02): 192-204
DOI: 10.1055/s-0038-1649421
Originalarbeiten — Original Articles — Travaux Originaux
Schattauer GmbH

Urokinase Levels in Urine after Nicotinic Acid Injection[*]

R Holemans**)
1   Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
,
D McConnell
1   Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
,
J.G Johnston
1   Department of Pathology, University of North Carolina School of Medicine, Chapel Hill, North Carolina
› Author Affiliations
Further Information

Publication History

Publication Date:
24 July 2018 (online)

Summary

1. Blood fibrinolytic activity and urokinase excretion were studied in a group of young healthy male subjects before and after intravenous injection of nicotinic acid. Although each of the subjects had a marked increase in blood fibrinolytic activity after injection of nicotinic acid, there was no significant change in urokinase excretion.

2. These data do not support the theory that urokinase is filtered blood activator of plasminogen. It is suggested that release of urokinase into urine is primarily dependent on the time of contact between urine and walls of collecting ducts and other parts of the urine conducting system.

*) This investigation was supported by USPHS Grant HE-06350 from the National Institutes of Health and by an institutional grant from the American Cancer Society.


**) Presently Morris Denkin Fellow in Hematology, Albert Einstein Medical Center, Northern Division, and Instructor of Hematology, Temple University Medical School, Philadelphia, Pa., U.S.A.


 
  • References

  • 1 Macfaricine E. G, Pilling J. Fibrinolytic activity of normal urine. Nature (Lond) 159: 779 1947;
  • 2 Williams J. R. B. The fibrinolytic activity of urine. Brit. J. exp. Pathol 32: 530 1951;
  • 3 Sobel G. W, Mohler SR, Jones N. W, Dowdy A. B. G, Guest M. M. Urokinase : An activator of plasma profibrinolysin extracted from urine. Amer. J. Physiol 171: 768 1952;
  • 4 Astrup T, Sterndorff I. An activator of plasminogen in normal urine. Proc. Soc. exp. Biol. (N.Y) 81: 675 1952;
  • 5 Smyrniotis F. E, Fletcher A. P, Alkaersig N, Sherry S. Urokinase excretion in health and its alteration in certain disease states. Thrombos. Diathes. haemorrh. (Stuttg) 03: 257 1959;
  • 6 Von Kaidla K. N, Swan H. Clotting deviations in man during cardiac bypass: fibrinolysis and circulating anticoagulant. J. thorac. Surg 36: 519 1958;
  • 7 Gelander D. R, Guest M. M. The biochemistry and physiology of urokinase. Amer. J. Cardiol 06: 409 1960;
  • 8 AIJcjaer K, Astrup T. The stability of the plasminogen activator in urine. In: Proc. 6th Congr. Europ. Soc. Haematol., Copenhagen; 1957: 472 S. Karger, Basel 1958.
  • 9 Ladehoff A. A. The content of plasminogen activator in the human urinary tract. Scand. J. clin. Lab. Invest 12: 136 1960;
  • 10 Holemans R, McConnell D. Urokinase levels in urine after injection of nicotinic acid. Clin. Res 13: 36 1964;
  • 11 Loomis E. G, George Jr. G, Ryder A. Fibrinolysin: nomenclature, unit, assay, preparation and properties. Arch. Biochem 12: 1 1947;
  • 12 Owren P. A. The coagulation of blood. Investigations on a new clotting factor. Acta med. scand. Suppl 194: 125 1947;
  • 13 Ploug J, Kjeldgaard N. O. Urokinase: an activator of plasminogen from human urine. I. Isolation and properties. Biochem. biophys. Acta (Amst) 24: 278 1957;
  • 14 Astrup T, Müllertz S. The fibrin plate method for estimating fibrinolytic activity. Arch. Biochem 40: 346 1952;
  • 15 Holemans R. Increase in fibrinolytic activity by venous occlusion. J. appl. Physiol 18: 1123 1963;
  • 16 Lassen M. Heat dénaturation of plasminogen in the fibrin plate method. Acta physiol, scand 27: 371 1953;
  • 17 Scheffé H. The Analysis of Variance. 73 John Wiley & Sons; New York: 1959
  • 18 Fletcher A. P, Bieclerman O, Moore D, Alkjaersig N, Sherry S. Abnormal plasminogenplasmin system activity (fibrinolysis) in patients with hepatic cirrhosis : its cause and consequences. J. clin. Invest 43: 681 1964;
  • 19 Braunsteiner H, Sailer S. Über V eränderungen der Lymphozytengröße durch Nikotinsäure. Wien Z. inn. Med 40: 6 1959;
  • 20 Oliver J, MacDowell M, Lee Y. G. Cellular mechanisms of protein metabolism in the nephron. I. The structural aspects of proteinuria; tubular absorption, droplet formation, and the disposal of proteins. J. exp. Med 99: 589 1954;
  • 21 Todd A. S. The histological localization of fibrinolysin activator. J. Pathol. Bacteriol 78: 281 1959;
  • 22 McConnell D, Johnston J. G, Young I, Holemans R. Localization of plasminogen activator in kidney tissue. (Submitted for publication.)
  • 23 Terry R, Hctwkins D. R, Church E. H, Whipple G. H. Proteinuria related to hyperproteinemia in dogs following plasma given parenterally. A renal threshold for plasma proteins. J. exp. Med 87: 561 1948;
  • 24 Dunn M, Martins J, Reissmann K. R. The disappearance rate of glutamic oxalacetic transaminase from the circulation and its distribution in the body’s fluid compartments and secretions. J. Lab. clin. Med 51: 259 1958;
  • 25 Mason E. E, Ghernigoy F. A, Cadwell R. E, Burke J. P. Clinical study of mild renal ischemia. Surg. Gynec. Obstet 119: 293 1964;
  • 26 Warren B. A. Fibrinolytic properties of vascular endothelium. Brit. J. exp. Pathol 44: 365 1963;
  • 27 Bjerrehus I. Fibrinolytic activity of urine. Scand. J. clin. Lab. Invest 04: 179 1952;
  • 28 Holemans R. Enhancing the fibrinolytic activity of the blood by vasoactive drugs. Med, exp. (Basel) 09: 5 1963;